Literature DB >> 21550507

Embolization during treatment of deep venous thrombosis: incidence, importance, and prevention.

Santiago Herrera1, Anthony J Comerota.   

Abstract

The standard of care for the treatment of acute deep venous thrombosis (DVT) is anticoagulation, which often prevents the formation of new thrombus and reduces the risk of pulmonary embolism (PE) but fails to eliminate the clot burden. Patients who have thrombus remaining in their deep venous system despite therapeutic anticoagulation are at high risk for developing symptoms of the postthrombotic syndrome, a debilitating condition that adversely affects their quality of life. Strategies of thrombus removal for acute DVT, such as operative thrombectomy, catheter-directed thrombolysis, and pharmacomechanical techniques, are designed to avoid postthrombotic morbidity by restoring patency to the deep veins, but there is concern that these techniques may result in fragmentation of clot and pulmonary embolization. Careful patient evaluation before treatment is essential for preventing complications and often reveals asymptomatic pulmonary emboli in as many as 50% of patients. Nonobstructive or free-floating thrombus in the vena cava is a risk factor for procedure-related embolization and is frequently an indication for the use of vena caval filtration. A review of the literature on acute DVT treated by anticoagulation alone or with strategies of thrombus removal reveals that pulmonary embolization is an infrequent occurrence. Treatment with anticoagulation alone, however, increases the risk of patients developing symptoms of the postthrombotic syndrome, whereas thrombus removal strategies reduce postthrombotic morbidity without increasing the risk of embolization.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550507     DOI: 10.1053/j.tvir.2011.01.002

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  6 in total

1.  Feasibility of continuous, catheter-directed thrombolysis using low-dose urokinase in combination with low molecular-weight heparin for acute iliofemoral venous thrombosis in patients at risk of bleeding.

Authors:  Guoping Chen; Wangyin Shi; Xu He; Wensheng Lou; Liang Chen; Jianping Gu
Journal:  Exp Ther Med       Date:  2017-01-04       Impact factor: 2.447

2.  Mathematical modeling of blood clot fragmentation during flow-mediated thrombolysis.

Authors:  Franci Bajd; Igor Serša
Journal:  Biophys J       Date:  2013-03-05       Impact factor: 4.033

3.  Novel isoguanine derivative of unlocked nucleic acid-Investigations of thermodynamics and biological potential of modified thrombin binding aptamer.

Authors:  Weronika Kotkowiak; Tomasz Czapik; Anna Pasternak
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

4.  Study the effect of static magnetic field intensity on drug delivery by magnetic nanoparticles.

Authors:  Abbas Moghanizadeh; Fakhreddin Ashrafizadeh; Jaleh Varshosaz; Antoine Ferreira
Journal:  Sci Rep       Date:  2021-09-10       Impact factor: 4.996

5.  The therapeutic efficacy and safety of traditional Chinese medicine injection combined with low-molecular-weight heparin on the acute lower extremity deep venous thrombosis: A protocol for systematic review and network meta-analysis.

Authors:  Mulan Zeng; Qian Liao; Yinjie Cui; Hongbo Tang; Maowen Yu
Journal:  Medicine (Baltimore)       Date:  2021-12-17       Impact factor: 1.817

6.  Combined pharmacomechanical thrombectomy with selective catheter-directed thrombolysis in patients with acute proximal deep vein thrombosis.

Authors:  Mustafa Aldağ; Ufuk Çiloğlu
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2022-04-27       Impact factor: 0.704

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.